HBI-3000
Sign in to saveAlso known as sulcardine
HBI-3000 (sulcardine sulfate) is an experimental drug candidate that is currently in phase II of human clinical trials as an antiarrhythmic agent. Clinical investigation will test the safety and efficacy of HBI-3000 as a treatment for both atrial and ventricular arrhythmias.
~3 min read
Encyclopedic overview
8 sectionsContents
- The molecular problem
- Mechanism of action in ventricular myocytes
- Studies
- Animal model
- Cellular isolation
- Human studies
- See also
- References
{{Chembox | ImageFile = sulcardine.svg | ImageClass = skin-invert-image | ImageSize = 200px | PIN = N-({4-Hydroxy-3,5-bis[(pyrrolidin-1-yl)methyl]phenyl}methyl)-4-methoxybenzene-1-sulfonamide | OtherNames = |Section1= |Section2= |Section3= }}
HBI-3000 (sulcardine sulfate) is an experimental drug candidate that is currently in phase II of human clinical trials as an antiarrhythmic agent. Clinical investigation will test the safety and efficacy of HBI-3000 as a treatment for both atrial and ventricular arrhythmias.
Excerpted from Wikipedia’s “HBI-3000” article, available under the CC BY-SA 4.0 licence.